Research assistance

We can help you find what you need. Call us or write us:
US: 800.298.5699
Int'l: +1.240.747.3093
Need help in your search?
 

Matching geography

Reports matching your search in:
 
 

Join Alert Me now!

Receive bi-weekly email alerts on new market research

Sign up today!
 

Regulation & Policy: market research reports

1594

Reports in this category will address the important role of regulation and policy in the healthcare market. As a highly regulated industry in most countries, healthcare marketers need to be aware of regulations in the countries where they sell products. Regulation will commonly refer to the actions of administrative bodies and existing laws, where as Policy would include potential laws and partial actions of state legislatures or congress.
Given that regulatory activity in the healthcare industry is intense and that policy debates are numerous, pharmaceutical or device markets need an awareness of what laws apply to their products.

In the United States drugs, diagnostics and medical devices are regulated by the Food and Drug Administration (FDA). The FDA is an agency of the United States Department of Health and Human Services, one of the United States federal executive departments. The FDA is responsible for protecting and promoting public health through the regulation and supervision of food safety, tobacco products, dietary supplements, prescription and over-the-counter pharmaceutical drugs (medications), vaccines, biopharmaceuticals, blood transfusions, medical devices, electromagnetic radiation emitting devices (ERED), veterinary products, and cosmetics.

The FDA derives its power from the Food, Drug and Cosmetic Act,[7] (Passed in 1938 and amended since) and are codified in Title 21, Chapter 9 of the United States Code. Some other laws that impact the FDA’s authority is Public Health Service Act, parts of the Controlled Substances Act, the Federal Anti-Tampering Act.

RSS Feeds

Regulation & Policy market research reports and industry analysis

< prev 1  2  3  4  5  6  7  8  9  10  next >
Central America Pharmaceuticals and Healthcare Report Q1 2013
1/16/2013 | published by: Business Monitor International
... opportunities forgeneric drugmakers from neighbouring Latin American countries and India. We highlight that Costa Ricaand Panama can be the premier countries in the region for foreign drugmakers to expand their presence. Headline Expenditure Projections Pharmaceuticals: ...  |  more...
$1,175.00
Indonesia Pharmaceuticals & Healthcare Industry 2H12
1/14/2013 | published by: Emerging Markets Direct Reports
... support and pharmaceutical trade. It also covers the market trends and outlook, regulatory changes, counterfeit drugs, industry SWOT analysis and market outlook, plus profile, comparative matrix and SWOT analysis of the leading players: PT Kalbe ...  |  more...
$450.00
Botanical and Plant-Derived Drugs: Global Markets
1/1/2013 | published by: BCC Research
... from 2011, estimates for 2012, and projections of compound annual growth rates (CAGRs) through 2017 A focus on legal, prescription-required therapeutic medicines sold in the open market; the study does not specifically cover herbals generally ...  |  more...
$4,850.00
Generic Growth Strategies - Market Driven by Impending Patent Cliff, Declining R&D Productivity and Government Initiatives to Reduce Healthcare Costs
12/14/2012 | published by: GBI Research
... Strategies - Market Driven by Impending Patent Cliff, Declining R&D Productivity and Government Initiatives to Reduce Healthcare Costs”. The report provides a comprehensive overview of the generic drugs market in the US, the top five ...  |  more...
$3,500.00
Healthcare, Regulatory and Reimbursement Landscape - Denmark
12/12/2012 | published by: GlobalData
... on Denmark`s healthcare, regulatory and reimbursement landscape. It identifies the key trends in the healthcare market and provides insights into the demographic, regulatory and reimbursement landscape and healthcare infrastructure. Most importantly, it provides valuable insights ...  |  more...
$1,995.00
Healthcare, Regulatory and Reimbursement Landscape - Venezuela
12/5/2012 | published by: GlobalData
... on the healthcare, regulatory and reimbursement landscape of Venezuela. The report identifies the key trends in the healthcare market of Venezuela. The report also provides insights into the demographic, regulatory and reimbursement landscapes and the ...  |  more...
$1,995.00
Healthcare, Regulatory and Reimbursement Landscape - Israel
12/5/2012 | published by: GlobalData
... healthcare, regulatory and reimbursement landscape, it identifies the key trends in the healthcare market and provides insights into the demographic, regulatory, and reimbursement landscape and healthcare infrastructure. Most importantly, the report provides valuable insights into ...  |  more...
$1,995.00
Healthcare, Regulatory and Reimbursement Landscape - Morocco
11/30/2012 | published by: GlobalData
... healthcare, regulatory and reimbursement landscape, this report identifies the key trends in the Morocco healthcare market, as well as providing insights on the demographic, regulatory, and reimbursement landscape, and the healthcare infrastructure of Morocco. Most ...  |  more...
$1,995.00
Healthcare, Regulatory and Reimbursement Landscape - Turkey
11/30/2012 | published by: GlobalData
... Turkey’s healthcare, regulatory and reimbursement landscape. It identifies the key trends in the healthcare market and provides insights into the demographic, regulatory and reimbursement landscape and healthcare infrastructure. Most importantly, the report provides valuable insights ...  |  more...
$1,995.00
Healthcare, Regulatory and Reimbursement Landscape - The Netherlands
11/20/2012 | published by: GlobalData
... and analysis regarding the healthcare, regulatory, and reimbursement landscape in the Netherlands. It identifies key trends in the healthcare market and provides insights into the demographic, regulatory, and reimbursement landscape, and the healthcare infrastructure. Most ...  |  more...
$1,995.00
2012 China New Medical Reform Policy Specific Analysis and the Influence on Medical Industry
11/14/2012 | published by: Huidian Research
... on provinces added list. Besides, it also had a specific analysis on marketing channel of China medicine enterprises under New Medical Reform Policy. Generally, the report can provide advantageous reference for insiders and help you ...  |  more...
$2,600.00
Active Pharmaceutical Ingredients (API) Global Market to 2017 - Growth in Developing Markets to Come From Cost Efficient Manufacturing and Rising Domestic Demand
11/9/2012 | published by: GBI Research
... - Growth in Developing Markets to Come From Cost Efficient Manufacturing and Rising Domestic Demand” provides detailed insight into the global APIs market. The research presents detailed analysis and forecasts of the major economic and ...  |  more...
$3,500.00
Active Pharmaceutical Ingredients (APIs) Market in Asia Pacific to 2017 - Increasing Penetration in China and India Coupled with Low Cost Manufacturing to Fuel Regional Growth
11/9/2012 | published by: GBI Research
... in Asia Pacific to 2017 - Increasing Penetration in China and India Coupled with Low Cost Manufacturing to Fuel Regional Growth”, provides a detailed insight into the Asia-Pacific API market. The research presents detailed analysis ...  |  more...
$3,500.00
China Pharmaceuticals & Health Care Industry 2H12
11/6/2012 | published by: Emerging Markets Direct Reports
... trends and outlook, social health care insurance system, traditional Chinese medicine, over-the-counter and vaccines, plus the profile, comparative matrix and SWOT analysis of the industry leading players: Shanghai Pharmaceuticals Holding Co. Ltd., China National Accord ...  |  more...
$480.00
Global Healthcare Cold Chain Logistics Market Report & Forecast: 2012-2017
11/5/2012 | published by: IMARC
... firms, finds that the total size of the healthcare cold chain logistic services market is expected to expand from its current figures of US$ 6.7 billion to nearly US$ 10.7 billion by 2017. This report, ...  |  more...
$1,200.00
Chinese CRO Company Report - Tigermed Consulting Co., Ltd.
11/1/2012 | published by: JZMed, Inc.
... as competent as those top tier players in the same service sector of the global pharma outsourcing industry. To help global pharma outsourcing companies and professional service providers as well as venture capital investors better ...  |  more...
$395.00
Market Access Taiwan
11/1/2012 | published by: JustPharmaReports.com
... be modified and the importance of health technology assessment (HTA) reaffirmed. The Cross-Strait Co-operation Agreement on Medicine and Public Health Affairs with mainland China might be of even greater significance in the longer term as ...  |  more...
$1,420.00
Chinese CRO Company Report - Beijing Genomic Institute (BGI)
11/1/2012 | published by: JZMed, Inc.
... as competent as those top tier players in the same service sector of the global pharma outsourcing industry. To help global pharma outsourcing companies and professional service providers as well as venture capital investors better ...  |  more...
$395.00
Healthcare, Regulatory and Reimbursement Landscape - Saudi Arabia
10/31/2012 | published by: GlobalData
... the Saudi Arabian healthcare, regulatory, and reimbursement landscape, this report identifies the key trends in the healthcare market, and provides insights on the demographic, regulatory, and reimbursement landscape, and healthcare infrastructure. Most importantly, the report ...  |  more...
$1,995.00
Global Pharmaceutical Market Report & Forecast: 2012-2017
10/10/2012 | published by: IMARC
... would impact the course of its growth. These transitions include a shift of growth from the developed to the emerging markets, an increasing focus on biopharmaceuticals compared to small molecule drugs and an increasing preference ...  |  more...
$1,400.00
Healthcare Landscape, Outlook, and Growth Opportunities in Mexico 2011-2015
10/4/2012 | published by: Frost & Sullivan
... rate (CAGR) from 2011 to 2015 will be will be examined and compared to the rest of Latin America. The economic recovery and the interest of the government to create more equality are generating an ...  |  more...
$4,500.00
Healthcare Reform: California-State Exchanges and Medicaid Expansion Implications for Key Health Insurers and Pharmaceutical Manufacturers
10/1/2012 | published by: Pharmspective
... low managed care penetration. California is likely to have one of the most robust State Exchanges in the post-ACA landscape as it leads the nation in developing the required infrastructure to implement the new insurance ...  |  more...
$4,500.00
Healthcare Reform: Texas-State Exchanges and Medicaid Expansion Implications for Key Health Insurers and Pharmaceutical Manufacturers
10/1/2012 | published by: Pharmspective
... the Affordable Care Act. With the largest uninsured population in the country, Texas is likely to see significant competition for this group once the political rhetoric subsides. The large Medicaid influx will certainly impact access ...  |  more...
$4,500.00
Healthcare Reform: State Exchanges-Opportunities and Threats for Key Health Insurers and Pharmaceutical Manufacturers
10/1/2012 | published by: Pharmspective
... to compete in a post-Affordable Care Act era. Changes to the market access landscape facing pharmaceutical manufacturers in the U.S. are the foundation for this new Pharmspective research report, which provides a detailed look at ...  |  more...
$22,000.00
Biopharmaceutical Manufacturing in India, China and South Korea - Regulatory Framework, Infrastructure Support and Discovery Funding Create an Environment Conducive to Growth
10/1/2012 | published by: GBI Research
... report, “Biopharmaceutical Manufacturing in India, China and South Korea - Regulatory Framework, Infrastructure Support and Discovery Funding Create an Environment Conducive to Growth”. The report provides an analysis of biopharmaceuticals approved in 2010 and 2011, ...  |  more...
$3,500.00
< prev 1  2  3  4  5  6  7  8  9  10  next >